DB-1310

Home > Research > Product pipeline > DB-1310

DB-1310

Back

· Overexpression in multiple tumor types and associated with drug resistance

· Pathway synergies with HER2 and EGFR dimerization

· Subsequent therapy amid growing HER2 ADC r/r population

Main highlights of drug design

· Binding novel epitope on domain I of HER3. Partially block HER2/HER3 and NRG/HER3 interaction

· Higher affinity than U3-1402

· High internalization capability

Advantages and Characteristics

CLINICAL DATA

· Out of 18 efficacy-evaluable EGFRm NSCLC patients across all dose levels from 1.5 to 5.5 mg/kg(1)1.uORR of 39% and uDCR of 94.4%
· Manageable safety profile with 57 patients treated(1) ≥Grade 3 TRAEs 19.3%

DEVELOPMENT PLAN

· NSCLC 1.Osimertinib combo in EGFRm NSCLC with 1L opportunity
· BC
1.Trastuzumab combo in post-Enhertu® HER2+ BC
2.Post-Trodelvy® in TNBC
· CRPC

KEY EXPECTED CATALYSTS

· Multiple data read-out in 2025 including DB-1310 + Osimertinib in EGFRm NSCLC